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Expression profiling of the ubiquitin 
conjugating enzyme UbcM2 in murine brain 
reveals modest age-dependent decreases 
in specific neurons
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Abstract 
Background: UbcM2 is a ubiquitin-conjugating enzyme with roles in the turnover of damaged and misfolded pro-
teins, cell cycle progression, development, and regulation of the antioxidant transcription factor, Nrf2. Recent screens 
have identified binding partners of the enzyme that are associated with various neurodegenerative diseases, and our 
previous studies have shown that UbcM2 is enriched in retina and brain.
Results: In the current study, we characterized UbcM2 protein expression in various structures and cell types in the 
murine brain. Immunofluorescence analysis of paraffin-embedded brain sections revealed that UbcM2 is ubiquitously 
expressed throughout the brain, is enriched in hindbrain and cortex, and is robustly expressed in neurons. In contrast, 
the enzyme is undetectable in most astrocytes and microglia. As dysfunction of the ubiquitin proteasome system 
(UPS) has been linked to many age-related neurological diseases, we compared UbcM2 expression levels in young 
versus aged wild-type mice and found a global decrease in expression in aged brains, with reductions of 10 % or 
greater in five substructures (cerebellar granule cell layer, primary motor cortex, olfactory nucleus, superior colliculus, 
and secondary visual cortex).
Conclusions: These studies represent the first protein expression profiling of a ubiquitin-conjugating enzyme in the 
brain and support the notion that deficits in protein degradation and proteostasis associated with neurodegenerative 
diseases may be, in part, attributable to age-dependent reductions in the enzymatic machinery of the UPS.
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Background
The ubiquitin (Ub) proteasome system (UPS) is a major 
intracellular protein degradation pathway. The central pro-
tein of this pathway is Ub, a highly conserved 76 amino acid 
polypeptide that is conjugated to target proteins through 
a hierarchal enzyme cascade consisting of a Ub-activating 
enzyme (E1), a Ub-conjugating enzyme (E2), and a Ub 
ligase (E3). E3s can be single proteins or multi-subunit 
complexes that recruit and facilitate the transfer of Ub to 
substrates. Humans have at least two E1s, 36–40 E2s, and 
up to 1000 E3s [1]. Thus, a single E2 can partner with a host 
of E3s, and, likewise, a given E3 can engage multiple E2s. 
Ubiquitylation targets recipient proteins to a number of 
fates, the best studied of which is degradation by the 26S 
proteasome. Ubiquitylation has also been shown to regu-
late protein localization, DNA repair, signal transduction, 
and a host of other functions (reviewed in [2]). A distinct 
class of enzymes collectively referred to as de-ubiquitylat-
ing enzymes, or DUBs, counter ubiquitylation by removing 
Ub from substrates. The balance between ubiquitylation 
and de-ubiquitylation must therefore be finely tuned to 
maintain proteostasis and cellular fidelity.
Dysregulation of the UPS is associated with many 
pathologies, including cardiovascular, inflammatory, and 
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neurodegenerative diseases. UPS activity decreases in 
normal aging as well as in Alzheimer’s disease [3], Par-
kinson’s disease [4], and age-related macular degenera-
tion [5, 6]. Consequently, a cardinal hallmark of these 
diseases is the accumulation of toxic protein aggregates; 
these are often associated with oxidative and proteotoxic 
stress and damage [7]. In most disorders, it remains to be 
determined if decreased UPS activity is a primary cause 
or a secondary consequence of these neurodegenerative 
pathologies.
A great deal of work has been done to characterize the 
biochemical mechanisms employed by E2s and E3s, but 
few studies have focused on cataloging the expression 
profiles of these enzymes in different organs, tissues, and 
cell types. In the work reported here, we analyzed the 
protein expression profile of UbcM2 in the brain. This 
enzyme is a highly-conserved metazoan E2 that plays 
roles in proteasome-mediated turnover of proteins [8], 
cell cycle progression [9, 10], and regulation of the anti-
oxidant transcription factor, Nrf2 [11, 12]. The human 
and mouse protein sequences of UbcM2 are identical, 
and the human form is called UBE2E3. Although a com-
prehensive assessment of the in vivo functions of UbcM2 
has not been performed in higher organisms, a functional 
homolog in yeast has been shown to mediate the degra-
dation of misfolded and oxidatively-damaged proteins 
[8]. We have previously shown that the enzyme is ubiq-
uitously expressed throughout the body but is enriched 
in the retina and brain in mice [13]. We further charac-
terized the expression profile in the neuroretina as well 
as the retinal pigment epithelium [13]. Subsequently, 
high throughput screens for protein–protein interactions 
revealed that UbcM2 interacts with the Huntington’s 
Disease proteins HTT [14] and RNF2 [15] and with the 
spinocerebellar ataxia-associated protein ATXN1 [16]. 
More recently, UbcM2 was shown to play a major role in 
the ubiquitylation status of TDP-43, a DNA-binding pro-
tein found in aggregates of amyotrophic lateral sclerosis 
and subtypes of frontotemporal lobar degeneration [17]. 
These interactions prompted us to carry out a cell type- 
and structure-specific immunofluorescence analysis of 
UbcM2 in mouse brain tissue and to determine if expres-
sion of the enzyme is altered in aged mice. We report here 
the first assessment of the localization and abundance of 
an E2 in the brain. This study serves as a launching point 
for the characterization of E2s in both healthy and path-
ological brains with the hopes of better understanding 
how UPS deficits contribute to neuropathologies.
Results
Validation of the α‑UbcM2 antibody
To determine the protein expression profile of UbcM2 
in mouse brain, a rabbit polyclonal antibody raised 
against the N-terminal 58 residues of UbcM2 was affin-
ity purified and validated in HeLa cells treated with 
either control siRNA (siCON) or UbcM2-specific siRNA 
(siUbcM2). 3 days post-siRNA treatment, cells were fixed 
and immunostained with α-UbcM2 and nuclei were 
counterstained with DAPI. α-UbcM2 labeling revealed 
that the enzyme localized to the nucleus (Fig. 1A, panel 
c), as we reported previously [18, 19], and that the knock-
down efficiency was 60–70 % (data not shown). Western 
blot analysis from human retinal pigment epithelial cell-
derived lysates treated with siCON or siUbcM2 shows 
a single band at the size of UbcM2 (23 kDa) in siCON-
treated cells and loss of the band in siUbcM2-treated 
cells (Fig.  1B). Additional validation of α-UbcM2 came 
from analyzing mouse embryo fibroblasts (MEFs) har-
boring floxed alleles of UbcM2 and stably transduced 
with trimethoprim-inducible Cre recombinase. As shown 
in Fig. 1C, Cre was induced in three of the four cells in 
the field and led to ablation of the α-UbcM2 signal in 
all three cells. The cell lacking Cre expression retained 
UbcM2 immunolabeling. In cell lysates derived from 
mouse cerebellum (CB) and cortex (Ctx), α-UbcM2 
detected a single band of the predicted migration for the 
enzyme (Fig. 1D).
Fig. 1 Validation of α-UbcM2 antibody. A HeLa cells were treated 
with 12 pmol of control siCON siRNA (a, b) or UbcM2-specific siRNA 
(c, d) for 72 h before fixation and immunostaining with α-UbcM2 (b, 
d). Nuclei were counterstained with DAPI (a, c). 60×, size bar 10 µm. 
B RPE-1 cells were treated with siCON (left lane) or siUbcM2 (right 
lane) for 72 h and solubilized for western blot analysis with α-UbcM2. 
Anti-β-tubulin is used as a loading control. C UbcM2Flox/Flox MEFs 
expressing an inducible Cre recombinase were fixed and labeled with 
DAPI (a), α-UbcM2 (b), and α-Cre (c). 3 of the 4 cells express Cre and 
lose UbcM2 expression whereas the non-Cre expressing cell retains 
UbcM2 expression. D Cell lysates prepared from mouse cerebellum 
(CB) and cortex (Ctx) were analyzed by α-UbcM2 western blot analysis
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UbcM2 is expressed in neurons and oligodendrocytes 
of mouse brain
We next co-immunolabeled sagittal brain sections 
with α-UbcM2 and antibodies specific for various cell 
types resident in brain. Co-staining with an antibody 
against the nuclear neuronal marker NeuN revealed 
that the overwhelming majority of UbcM2 is expressed 
in neurons and that essentially all neurons express the 
enzyme (Fig.  2A). UbcM2 expression was also consist-
ently observed in CNPase-positive oligodendrocytes 
throughout brain (Fig.  2B). Within the limits of detec-
tion of the UbcM2 antibody, the enzyme was minimally 
detected or absent in most microglia, labeled by α-Iba1 
staining (Fig. 2C), and in astrocytes, labeled by α-GFAP 
staining (Fig. 2D). Curiously, a subpopulation of micro-
glia and astrocytes displayed robust UbcM2 expression, 
examples of which are depicted in representative images 
of hippocampal CA1 sections (white arrows in Fig. 2C, 
panel d, and Fig. 2D, panel d, respectively). What distin-
guishes these rare cells from the remainder of glial cells 
that do not express detectable levels of UbcM2 remains 
to be determined. Due to the prevalence of UbcM2 
in NeuN-positive cells (i.e., neurons), we focused the 
remainder of this study on quantitatively analyzing the 
relative expression levels of UbcM2 in neurons.
UbcM2 is universally expressed in neurons 
throughout mouse brain
Sagittal brain sections were probed with α-UbcM2 and 
α-NeuN to determine the relative expression of neuronal 
UbcM2 in 22 anatomically-distinct structures. A mouse 
brain atlas [20] was used during the sectioning and analy-
sis to ensure correct orientation using white matter, cer-
ebellum, and various structural markers as landmarks. 
These landmarks also ensured that studies compared 
the same sagittal plane(s) within each brain. Representa-
tive photomicrographs of UbcM2 staining in various 
substructures (Fig.  3A) demonstrate the range observed 
throughout the brain, with relatively high expression 
detected in pontine nuclei (Fig. 3A, panel c), intermediate 
levels detected in hippocampal CA1 and cingulate cortex 
(Fig. 3A, panels g and k, respectively), and relatively low 
levels observed in caudate putamen (Fig.  3A, panel o). 
Notably, UbcM2 was detected in all substructures 
Fig. 2 UbcM2 is expressed in neurons and oligodendrocytes but is undetectable in most microglia and astrocytes. Representative images from 
stained 7 μm, paraffin-embedded sagittal C57BL/6 brain sections of dorsal cortex and CA1, along with cerebellum (A, B) or thalamus (C, D). A 
Nuclear neuronal marker NeuN (green) and UbcM2 (red) with yellow indicating colocalization in the merged images (c, f, i). B–D Co-staining with cell 
type-specific marker CNPase for oligodendrocytes (B), Iba1 for microglia (C), or GFAP for astrocytes (D) shown in green with Hoechst (white, a, c, e) to 
mark nuclei or with UbcM2 (red, b, d, f). White arrowheads indicate oligodendritic (B), microglial (C), or astrocytic (D) nuclei. 60×, size bar 10 µm
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surveyed [Fig.  3B; Table  1 (“relative UbcM2 expression” 
column), and Additional file 1: Figure S1]. Relatively high 
expression was detected in hindbrain and many cortical 
areas, whereas hippocampus and several basal ganglia 
components exhibited lower expression of the enzyme 
(Fig. 3B, Additional file 1: Figure S1).
Fig. 3 Neurons express UbcM2 at relatively high levels in hindbrain and low levels in caudate putamen. A Representative images of 7 μm, paraffin-
embedded sagittal brain sections from a 4-month old C57BL/6 mouse. Anatomical regions shown are pontine nuclei (a–d), hippocampal CA1 (e–h), 
cingulate cortex (i–l), and caudate putamen (m–p). DNA is counterstained with Hoechst (white), and sections are immunostained for the nuclear 
neuronal marker NeuN (green) and UbcM2 (red). Co-localization of NeuN and UbcM2 is indicated by yellow in the merged images (d, h, l, p). 20×, size bar 
30 μm. B Brain substructure-specific UbcM2 expression as measured by fluorescence intensity relative to the area of highest expression (spinal trigemi-
nal nucleus). Error bars indicate 95 % confidence intervals. Disjoint confidence interval bars identify regions with significantly different UbcM2 levels
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UbcM2 expression is modestly decreased in aged mouse 
brain
As the function and efficiency of the UPS decline with 
age (reviewed in [21, 22]), we next compared the expres-
sion levels of UbcM2 in the brains of young and aged 
mice. Young mice were 1–4 months old, and aged mice 
ranged from 10–25 months. Sagittal brain sections were 
examined for neuronal UbcM2 expression as measured 
by average cellular α-UbcM2-derived fluorescence inten-
sity in NeuN-positive nuclei. An analysis consisting of 
22 distinct substructures revealed a modest but statisti-
cally significant global decrease of UbcM2 expression of 
5.5 % (p value = 0.046) in aged animals as compared to 
their strain-matched, younger counterparts (Fig.  4A, B; 
Table 1). Five substructures in particular (cerebellar gran-
ule cell layer, primary motor cortex, olfactory nucleus, 
superior colliculus, and secondary visual cortex) exhib-
ited statistically significant decreases of 10 % or more as a 
function of age (Fig. 4A, C; Table 1, italic entries).
UbcM2 expression is unchanged in aged Nrf2‑deficient 
brains relative to aged wildtype
We have shown that UbcM2 regulates Nrf2 [11, 12], an 
antioxidant transcription factor that induces the expres-
sion of genes encoding cytoprotective proteins and 
enzymes involved in redox homeostasis and proteosta-
sis [23–25]. Thus, genetic ablation of Nrf2 is predicted to 
increase the abundance of oxidatively-damaged proteins 
destined for Ub-mediated degradation. Nonetheless, we 
did not observe altered levels or expression patterns of 
UbcM2 in aged cohorts of this knockout strain relative to 
age-and strain-matched controls (Fig. 5A; Table 2). Con-
sistent with these data, we found by western blotting that 
the brains of these animals do not accumulate polyUb 
aggregates or heat shock protein 70 (HSP70), markers of 
disrupted proteostasis (Fig.  5B), or have increased anti-
Ub labeling in paraffin sections (Fig. 5C). These data indi-
cate that the steady-state level of overt proteotoxic stress 
in Nrf2 knockout brains is relatively minimal. Curiously, 
these knockout mice reportedly undergo spontaneous 
retinal degeneration in an age-dependent fashion [26]. 
We surmise that this phenotype is a function of the retina 
being exposed to the additional stress derived from con-
stant photo-oxidative challenge throughout the life of the 
animal.
Discussion
The principal advance of this work is that it represents the 
first description of the cell- and structure-specific expres-
sion and distribution of a UPS E2 in the mouse brain. Our 
previous studies to develop a global UbcM2 knockout 
mouse strain resulted in a failure to produce homozygous 
knockouts, consistent with UbcM2 loss causing embry-
onic lethality (S. Plafker, unpublished results) and knock-
down of the enzyme inducing a cell cycle arrest/exit [10]. 
The expression profiling described in the present study is 
therefore a requisite first step for directing future efforts 
at genetically ablating the enzyme in specific anatomical 
structures of the brain. Such knockouts could provide 
useful models to determine if and how UPS deficits con-
tribute to neurodegeneration.
By immunological staining of paraffin-embedded 
murine brain sections with a highly specific antibody, we 
found that UbcM2 is ubiquitously expressed in neurons 
and oligodendrocytes but is undetectable in the major-
ity of microglia and astrocytes (Fig. 2). These data largely 
reflect transcriptional profiling data for isolated astro-
cytes, neurons, and oligodendrocytes showing enrich-
ment of the UbcM2 transcript (referred to by the human 
Table 1 UbcM2 expression is decreased in  the neurons 
of specific substructures of the mouse brain
The expression levels of UbcM2 in the brains of young and aged mice were 
measured and compared by average cellular α-UbcM2-derived fluorescence 
intensity in NeuN-positive nuclei. A 5.5 % global decrease of UbcM2 expression 
was detected in aged versus their strain-matched, younger counterparts. The 
italic numbers indicate decreases of UbcM2 expression of 10 % or greater in 
particular substructures of the brain
Brain structure Relative UbcM2 
expression
UbcM2 expression 
% change in aged 
mice
P value
CA1 0.776 −11.518 0.0590
CA2 0.711 −9.714 0.1500
CA3 0.801 −7.614 0.1800




Cingulate ctx 0.679 1.317 0.8900
Dentate gyrus 0.630 1.806 0.8100




Inferior colliculus 0.687 −7.692 0.2800
Motor ctx-primary 0.951 −11.111 0.0260
Motor ctx-secondary 0.984 −5.372 0.2600
Nucleus accumbens 0.634 −7.051 0.3500
Olfactory nu 0.927 −10.526 0.0410




Sensory ctx-primary 0.825 −10.837 0.0560
Spinal trigeminal nu 1.000 −8.943 0.0600




Thalamus-ventral 0.720 −0.847 0.9000
Visual ctx-secondary 0.923 −11.454 0.0290
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gene name, UBE2E3), as well as many other components 
of the UPS, in neurons and oligodendrocytes relative to 
astrocytes [27]. Approximately half the amount of UbcM2 
mRNA was detected in astrocytes relative to neurons, 
and this level of astrocyte expression is likely due to the 
fact that the isolated cells were derived from very young 
mouse brains and cultured several days before analysis. 
UbcM2 is expressed in replicating cells and is necessary 
for cell replication [10]. Consistent with this, we hypoth-
esize that the rare population of UbcM2-expressing 
astrocytes and microglia are likely replicating. Due to the 
prevalence of UbcM2 in neurons, we quantified the rela-
tive expression of the enzyme in NeuN-positive nuclei 
in 22 brain structures (Fig. 3, Additional file 1: Figure S1; 
Table  1). We observed relatively robust UbcM2 expres-
sion in hindbrain and cortical structures and lower 
expression in hippocampus and several basal ganglia 
components. As UPS dysfunction has been linked to mul-
tiple age-associated neuropathologies, we also examined 
whether UbcM2 expression levels change as a function 
of age. We observed a modest 5.5  % global decrease in 
neuronal UbcM2 expression in aged brain with a more 
marked decrease (>10 %) in 5 substructures, namely cer-
ebellar granule cell layer, primary motor cortex, olfactory 
nucleus, superior colliculus, and secondary visual cortex 
(Fig. 4; Table 1).
Our results are largely consistent with a qRT-PCR 
analysis of UbcM2 mRNA localization in mouse embryo 
[28]. Similar to our findings of protein expression in adult 
mice [13], UbcM2 mRNA was enriched in embryonic 
brain with lowest expression in heart and intermediate 
levels in lung, liver, and kidney. Within embryonic brain, 
high mRNA levels were detected in cortex and hindbrain, 
but unlike UbcM2 protein expression, the mRNA was 
also enriched in thalamus, midbrain, and hippocampus at 
various stages of embryonic development. These differ-
ences may be attributable to changes in UbcM2 expres-
sion during development versus post-development and/
or a discrepancy between protein and mRNA levels due 
to translational or degradative regulation.
Although genetic mutations of UbcM2 have not been 
linked to neurodegeneration to date, the enzyme is highly 
enriched in numerous brain areas devoted to motor out-
put, including primary and secondary motor cortices, 
Fig. 4 UbcM2 expression is decreased in aged mouse brains. A Representative photomicrographs showing decreased UbcM2 expression in aged 
(b, d, f, h, j) relative to young control (a, c, e, g, i) brains in the 5 structures with >10 % differences. 20×, size bar 30 μm. B Average expression of 
UbcM2 in whole brain, consisting of the analysis of 22 substructures, indicating a 5.5 % global decrease in aged brain relative to young control. 
n = 5 in triplicate; p value = 0.046. C Average UbcM2 expression in the 5 substructures that exhibited a >10 % decrease. Asterisks denote p < 0.05. 
CB (cerebellum granule cells), MC1 (primary motor cortex), ON (olfactory nucleus), SC (superior colliculus), VC2 (secondary visual cortex)
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reticular formation, pontine nuclei, facial nucleus, and 
cerebellum. These data fit with the notion that UbcM2 
may contribute to motor function and thereby potentially 
play a role in motor deficits that characterize a number 
of neurodegenerative diseases. Notably, GWAS data indi-
cate that UbcM2 can interact with ATXN1 [16], a protein 
linked to spinocerebellar ataxia (SCA). This condition 
is marked by motor deficits resulting from cerebellar 
degeneration, dysfunction of both the UPS and the mito-
chondria, and an accumulation of Ub-positive aggregates 
[29]. Interestingly, UbcM2 is enriched in the cerebellum 
and appears to decline with age (Fig. 4A; Table 1). More-
over, UbcM2 has been shown to ubiquitylate TDP-43 
[17], a protein involved in amyotrophic lateral sclerosis 
(ALS). ALS is a motor disease that can result from degen-
eration of upper motor neurons located in the motor 
cortex or reticular formation of the brainstem, both of 
which express relatively high levels of UbcM2 (Fig.  3B; 
Table  1). These interactions potentially link the enzyme 
to the neurodegenerative motor disorders of SCA and 
ALS. UbcM2 could also be linked to non-pathological, 
age-related motor deficits as the enzyme is abundant in 
the cortico-ponto-cerebellar tract, an important motor 
pathway, and decreases in motor cortex and cerebellar 
granule cells with age. Both of these structures degener-
ate in normal aging and contribute to age-related motor 
dysfunction [30].
Conclusions
In conclusion, we have performed the first protein 
expression profiling of a Ub-conjugating enzyme in 
the mouse brain. We show that the class III E2 UbcM2 
is ubiquitously expressed in neurons and oligodendro-
cytes but is not prevalent in microglia or astrocytes. 
By quantifying relative α-UbcM2-derived fluorescence 
from immunohistochemically stained mouse brain sec-
tions, we have determined the relative structure-specific 
neuronal expression of the enzyme. Further, we have 
observed a modest decrease in neuronal UbcM2 expres-
sion in particular sub-structures of the aged mouse brain.
Methods
Antibodies
α-UbcM2 was raised in rabbits against a recombi-
nant His6-S-tagged polypeptide corresponding to 
the unique N-terminal 58 residues of the enzyme 
Fig. 5 UbcM2 expression is not altered in Nrf2-deficient brains. A Average expression of UbcM2 in whole brain, consisting of the analysis of 20 sub-
structures, indicating no change in aged, Nrf2-deficient brain relative to aged, strain-matched controls. n = 5 in triplicate. B Western blot analyses of 
Nrf2 knockout and age/strain-matched wt mice to detect markers of proteotoxicity and stress. Antibodies used are listed to the right of each panel, 
and the age and genotype of the mice are indicated above each lane. The positive control (+ctrl) for HSP70 induction and the accumulation of 
polyubiquitylated proteins is from retinal pigment epithelium (RPE-1) cells treated for 8 h with 10 µm proteasome inhibitor MG132 and harvested 
with 2 times concentrated Laemmli buffer. The vertical line between lanes 7 and 8 represents a lane in which molecular weight markers were run. 
The migration of these markers is indicated to the left. C Representative photomicrographs of dentate gyrus (a, b) and cerebellum (c, d) from aged 
Nrf2-deficient (92 week; b, d) and strain-matched control (98 week; a, c) brains immunolabeled with an α-ubiquitin antibody
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(MSSDRQRSDDESPSTSSGSSDADQRDPAAPEPEEQ 
EERKPSATQQKKNTKLSSKTTAK), as previously 
described [12]. Commercially-available, validated anti-
bodies used throughout these immunofluorescence stud-
ies include: mouse polyclonal α-GFAP (1:500; Neuromics 
MO22136), mouse monoclonal α-myelin CNPase (1:2500; 
Covance SMI-91R), mouse monoclonal α-Iba1 (1:200; 
EMD Millipore MABN92), mouse monoclonal α-NeuN 
(1:2000; EMD Millipore MAB377), mouse monoclonal 
α-ubiquitin (1:500; Santa Cruz sc-8017), and mouse mon-
oclonal α-cre recombinase (1:2000; Millipore MAB3120). 
Secondary antibodies used were Alexa546nm Fluor-conju-
gated goat α-rabbit IgG and Alexa488nm Fluor-conjugated 
goat α-mouse IgG (1:1000, Molecular Probes). Antibod-
ies used for western blotting include mouse monoclo-
nal α-HSP70 (1:1000; Enzo, Inc ADI-SPA-810), mouse 
monoclonal α-Ub (1:1000; Santa Cruz sc-8017), and 
mouse monoclonal anti-β-tubulin (1:1000; Sigma Aldrich 
T4026). Details for each are listed in Table 3.
Cell culture, siRNA transfections, and immunofluorescence
UbcM2-specific siRNA or control siCON siRNA 
(Dharmacon, Inc.) were combined with INTERFERin 
(Polyplus transfection) for 10 min at room temperature 
before being added to 35,000 HeLa or hTERT RPE-1 
(cat # CRL-4000; ATCC) cells seeded in 12-well dishes 
on glass coverslips. A final concentration of 10  nM 
siRNA was added to the cells in DMEM (cat. # 10-013-
CV; Mediatech, Inc.) supplemented with 10  % fetal 
calf serum (FCS), 100 units/mL penicillin, and 0.1 mg/
ml streptomycin sulfate. 72  h post-transfection, cells 
were fixed in 3.7 % formaldehyde in PBS for 15 min at 
room temperature and permeabilized in 0.2  % Triton 
X-100 in PBS for 10 min on ice. Cells were then incu-
bated in blocking solution consisting of 3  % bovine 
serum albumin (BSA) in PBS for 3 h before being incu-
bated in α-UbcM2 diluted at 1:500 in blocking solution 
Table 2 UbcM2 expression does not change in aged Nrf2-
deficient brains relative to wild type controls
Brain structure UbcM2 expression %  






Caudate putamen 5.078 0.61
Cerebellum-granule −2.908 0.66
Dentate gyrus −2.956 0.72
Globus pallidus 6.630 0.37
Inferior colliculus −5.409 0.77
Motor ctx-primary 4.739 0.42
Nu accumbens 1.304 0.89
Orbital ctx 8.293 0.19
Piriform ctx 5.063 0.40
Sensory ctx-primary −3.221 0.61
Spinal trigeminal nu 9.589 0.12
Substantia nigra 1.952 0.71
Superior colliculus 9.722 0.27
Thalamus-lateral −8.556 0.24
Thalamus-ventral −2.289 0.77
Visual ctx-secondary 7.426 0.26
Table 3 Antibodies used in this study
Antibody Immunogen Manufacturer, host, mono‑/poly‑clonal, catalog  
number, RRID
Conc. used
Anti-UbcM2 Recombinant His6-S-tagged unique N-terminal 
extension (MSSDRQRSDDESPSTSSGSSDAD 
QRDPAAPEPEEQEERKPSATQQKKNTKLSSKTTAK)
In-house, rabbit, polyclonal 1:500 (IHC)/ 
1:1000 (WB)
Anti-Cre recombinase aa 77-343 fusion protein EMD Millipore, mouse, monoclonal, MAB3120, 
RRID:AB_2085748
1:2000
Anti-GFAP Recombinant GFAP, boosts with GFAP purified from 
bovine spinal cord
Neuromics, mouse, polyclonal, MO22136, 
RRID:AB_2341541
1:500
Anti-myelin CNPase Purified human myelin CNPase Covance, mouse, monoclonal, SMI 91, RRID:AB_10120658 1:2500
Anti-Iba1 Linear peptide corresponding to human Iba1/AIF1 EMD Milipore, mouse, monoclonal, MABN92, 
RRID:AB_10917271
1:200
Anti-NeuN Purified cell nuclei from mouse brain EMD Millipore, mouse, monoclonal, MAB377, 
RRID:AB_2298772
1:2000
Anti-HSP70 Native human HSP70 Enzo, mouse, monoclonal, ADI-SPA-810,  
RRID:AB_10616513
1:1000
Anti-ubiquitin Amino acids 1-76 representing full length ub of 
bovine origin




Anti-β-tubulin Tubulin from rat brain Sigma-Aldrich, mouse, monoclonal, T4026, 
RRID:AB_477577
1:1000
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for 1  h at room temperature. Cells were subsequently 
washed in PBS, incubated in secondary antibody plus 
4′,6-diamidino-2-phenylindole (DAPI; 0.1  μg/mL) in 
blocking solution for 1  h, washed again, and mounted 
on glass slides.
To generate MEFs, pregnant UbcM2Flox/Flox mice were 
sacrificed 13.5  days post-coitus and embryos removed 
by manual dissection from amniotic sacs, washed with 
ethanol, and the limbs, tail, red organs, and head above 
the eyes were removed. The remaining material was 
minced with a sterile razor blade in 4.5 g/L glucose-con-
taining DMEM containing penicillin and streptomycin 
and trypsinized for 10 min at 37  °C. Non-soluble mate-
rial was removed by centrifugation, and the remaining 
cells were cultured in 4.5 g/L glucose-containing DMEM 
containing penicillin, streptomycin, and 10 % FCS. MEFs 
were subsequently transduced with a lentivirus express-
ing a trimethoprim-inducible Cre recombinase, and Cre 
expression was induced by adding 10  µM trimethoprim 
to the media for at least 24 h.
Mouse brain tissue preparation
All animal care was performed in compliance with The 
Oklahoma Medical Research Foundation Institutional 
Animal Care and Use Committee-approved protocol. 
Nrf2−/− mice (10–25 months) were backcrossed 10 gen-
erations into a C57BL6 background and have been pre-
viously described [26, 31]. C57BL/6 mice were used in 
the control (1–4  months) versus aged (10–25  months) 
analysis. Mice were euthanized by CO2 asphyxiation 
and decapitated to remove brains. Tissue was fixed in 
10  % neutral buffered formalin at 4  °C overnight then 
processed and paraffinized using an overnight proto-
col with ethanol, xylene, and paraffin equilibration in a 
Shandon Excelsior tissue processor (Thermo Scientific). 
Brains were cut into 7  μm-thick sagittal sections using 
a Leica Instruments Microtome (Model 2045 Multicut), 
mounted on charged glass slides, and warmed on a Lab-
Line Instruments slide warmer (Model 26020) overnight. 
A mouse brain atlas [20] was used throughout the sec-
tioning process to ensure correct orientation using white 
matter, cerebellum, and various structural markers as 
landmarks. These same landmarks were observed to 
ensure studies compared the same sagittal plane within 
each brain, although we observed very similar UbcM2 
expression levels in various planes of the same substruc-
tures within a brain (data not shown).
Immunohistochemistry
Slides were deparaffinized by washes in Histo-Clear 
(National Diagnostics) followed by serial washes in 
decreasing amounts of ethanol and then water. Heat-
induced epitope retrieval was performed using a Retriever 
2100 (Electron Microscopy Sciences) in the accompa-
nying R-buffer AG, and slides were allowed to cool in 
the retriever for 4–20 h. Slides were then washed in PBS 
and incubated in blocking solution consisting of 10  % 
goat serum and 3 % BSA in PBS for 1–3 h at room tem-
perature. Sections were incubated in α-UbcM2 (1:500) 
or α-Ubiquitin (1:500) and a cell-type specific antibody 
in blocking solution at 4 °C overnight. The following day, 
the slides were washed in PBS and incubated in secondary 
antibody and DAPI at 0.1 μg/mL or Hoechst33342 at 1 μg/
mL diluted in 3 % BSA in PBS for 1 h at room temperature 
in the dark. After a final PBS wash, slides were mounted 
using ProLong Gold (Cell Signaling Technology) and 
examined with a Nikon 80i microscope and DXM1200C 
camera. Images were captured using NIS-Elements soft-
ware (Nikon), and representative images were processed in 
Adobe Photoshop (Version 8.0). Of note, all sections quan-
titatively compared corresponded to a similar parasagit-
tal plane of the brain, were processed at the same time in 
parallel with the same diluted reagents, and were imaged 
using identical gain, exposure, and binning settings.
Western blotting
Brain lysates were prepared from 5  month-old female 
C57BL/6 mice that were euthanized by CO2 asphyxia-
tion and decapitated to remove brains for dissection of 
cerebellum and cortex on a cold block. Structures were 
lysed in a buffer consisting of 150  mM NaCl, 20  mM 
Tris [pH 8], 1 % Triton X-100, 2 mM EDTA, and 1 tab-
let phosphatase inhibitor (Thermoscientific PI 88266), 
homogenized with a pestle, and incubated on ice 1–2 h 
before sonication. Debris was removed by centrifuga-
tion, and supernatants collected for analysis. Brain or 
cell culture lysates were boiled in 2 times concentrated 
(2X) Laemmli solubilizing buffer (100 mM Tris [pH 6.8], 
2 % SDS, 0.008 % bromophenol blue, 2 % 2-mercaptoe-
thanol, 26.3 % glycerol, and 0.001 % Pyrinin Y), resolved 
by SDS-PAGE and transferred to nitrocellulose. Blots 
were blocked in 5 % nonfat milk/TBST (0.1 % Tween-20 
in Tris-buffered saline) before incubation with primary 
antibodies. All primary antibodies were diluted 1:1000 in 
5  % nonfat milk/TBST. Horseradish peroxidase (HRP)-
conjugated secondary antibodies were diluted in 5  % 
Milk/TBST, and blots were processed with enhanced 
chemiluminescence.
Neuronal UbcM2 expression analysis
For each genotype or age comparison, 5 animals were 
used per group as biological replicates, and per animal, 3 
sequential sections on 1 slide were analyzed as technical 
replicates such that a total of 15 brain sections from 5 ani-
mals represent each genotype/age group. A separate 20× 
picture was taken of each substructure analyzed, and all 
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cells (50–150 nuclei) were evaluated in each image. Only 
nuclear expression was observed and quantitated, as this 
study and our previous work demonstrate that UbcM2 is 
exclusively expressed in the nucleus [13]. UbcM2 expres-
sion was measured in terms of α-UbcM2-derived fluores-
cent intensity in NeuN-positive nuclei using NIH ImageJ 
software. Separate grayscale pictures were taken for each 
of the three channels corresponding to nuclei, NeuN, and 
UbcM2. In ImageJ, each raw NeuN image was subjected 
to a user-defined threshold such that only NeuN-positive 
areas were represented. The fluorescence intensity of 
each NeuN-positive cell was then measured in the cor-
responding raw UbcM2 image on a scale of 0–255 pixels. 
Each nuclear UbcM2 measurement was normalized to 
the background intensity of that image with background 
defined as an average value of 10 separate measurements 
of visually UbcM2-negative areas.
Statistical analysis
In each of the two comparative studies, namely young 
vs old and Nrf2 knockout vs wildtype, the enzyme 
level dependence on the covariates was analyzed by 
fitting a Linear Mixed Effects Model implemented as 
the lme function in the nlme R package. This function 
is essentially an extended version of the classical lin-
ear regression but is able to accommodate complex 
data collection design features such as nested layers 
and within-group correlation. The method formulation 
[32], computational method [33], and implementation 
of the model in R [34] have previously been described 
in detail. As described in the previous section, data 
collection design involved 3 embedded layers for each 
group (where group refers to old, young, Nrf2 knockout, 
or Nrf2 strain-matched wildtype control) as 50–150 
measurements (cells) per 22 (aged study) or 20 (Nrf2 
study) substructures were analyzed in three sequential 
brain sections per mouse. Accordingly, the data was 
analyzed by performing an unequal sample sizes multi-
level nested lme where protein level dependence on the 
fixed effects, namely variable (age or genotype), brain 
structure, and their interactions, was analyzed with the 
embedded data collection structure designated as a ran-
dom effect represented as Mouse/Replicate/Structure. 
Significance of UbcM2 expression changes in whole 
brain was assessed with the lme version of the ANOVA 
function applied on the lme object. Fixed effect coeffi-
cient significance tables were extracted with the tTable 
method while confidence intervals were returned by 
the intervals function in the nlme package (Tables 1, 2; 
Figs. 3B, 4B, C, 5A). Slight testing power boosting was 
achieved by using one-sided tests with the null hypoth-
esis matching the expectation that UbcM2 levels are 
lower in old mice.
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